Genetic reprogramming of cell fate and identity is a promising strategy for cell-based therapies and tissue regeneration. In particular, targeted manipulation of a few genes has been shown as a useful method for induced pluripotent stem (iPS) cell derivation, stem cell differentiation, and T-cell reengineering. Though rapid progress has been made, current methods for targeted genome manipulation are very inefficient and require many accessory factors, limiting their utility for effective cell reprogramming to control different levels of regulation and to coordinate the kinetic expression of large numbers of genes. The major goal of the research is to develop a novel modular and programmable RNA-guided platform that can be used to target multiple genes in a genome for transcriptional or epigenetic regulation, and to exploit its applications for iPS cell reprogramming and potentially other cell-based therapeutic approaches. The proposed platform is built on my recently demonstrated CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) interference (CRISPRi) system derived from the bacterial immune pathway, which is an RNA-guided method for transcriptional silencing of arbitrary genes in diverse host cells. The method requires only a single modified Cas protein (catalytically inactive) and a designed small guide RNA with a 20-basepair complementary region to any gene of interest, without genetically altering the target locus. To further develop the system as a novel cell-reprogramming platform, I will first perform high-throughput characterization experiments in bacteria as a model to quantify the determinants of RNA-guided regulatory efficiency and specificity. Mathematical models will be developed and used for the rational design of large RNA libraries for efficient and specific genome targeting. Second, to develop a programmable platform for various regulatory functions, I will extend the CRISPRi system as a modular DNA-binding system for use in mammalian cells. The system will be combined with protein effectors for different types of genome-scale targeted regulations, including transcription activation, transcription silencing, and heritable histone modification. I will also introduce the ability to regulate these functions using light, through the use of optogenetically controlled protein interactions. Third, as a test bed, I ill focus on using the programmable CRISPRi platform as an alternative and perhaps easier way to generate iPS cells. I will create light-gated transcription circuits to precisely control the expression program of endogenous transcription factors that are known to be important for iPS cell reprogramming. I will also use the CRISPRi platform to target and modify epigenetic regulation of these factors, and study if regulating epigenetic marks could achieve more efficient, more stable, and safer reprogramming. Together, these aims will address a critical barrier for cell reprogramming by providing a novel RNA-guided platform for sequence-specific regulation of multiple genes for various types of regulation. Further, the application will providea novel technological basis for constructing gene circuits to coordinate multiple genes for iPS cell generation, which is also directly applicable to other cell reprogramming applications such as stem cell differentiation and T-cell engineering.

Public Health Relevance

The ability to reprogram cells with a novel identity and developmental fate opens new doors in studying human physiology and disease and raises the possibility of repairing malfunctioning tissues. However, most cellular reprogramming applications remain inefficient, partly due to our inability to manipulate large numbers of genes on a genome-wide scale and in a controlled and programmable manner. To address this major challenge, the proposed research aims to develop a novel genetic platform for cell reprogramming that is more efficient, more stable and safer, using generation of induced pluripotent stem (iPS) cells as a test bed, which is also applicable to other cell-based therapy strategies for disease treatment and tissue regeneration.

National Institute of Health (NIH)
Office of The Director, National Institutes of Health (OD)
Early Independence Award (DP5)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Basavappa, Ravi
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Schools of Medicine
San Francisco
United States
Zip Code
Liu, Yanxia; Yu, Chen; Daley, Timothy Patrick et al. (2018) CRISPR Activation Screens Systematically Identify Factors that Drive Neuronal Fate and Reprogramming. Cell Stem Cell 23:758-771.e8
Zhou, Xin X; Zou, Xinzhi; Chung, Hokyung K et al. (2018) A Single-Chain Photoswitchable CRISPR-Cas9 Architecture for Light-Inducible Gene Editing and Transcription. ACS Chem Biol 13:443-448
Wang, Haifeng; Xu, Xiaoshu; Nguyen, Cindy M et al. (2018) CRISPR-Mediated Programmable 3D Genome Positioning and Nuclear Organization. Cell 175:1405-1417.e14
Daley, Timothy P; Lin, Zhixiang; Lin, Xueqiu et al. (2018) CRISPhieRmix: a hierarchical mixture model for CRISPR pooled screens. Genome Biol 19:159
Du, Dan; Roguev, Assen; Gordon, David E et al. (2017) Genetic interaction mapping in mammalian cells using CRISPR interference. Nat Methods 14:577-580
Peters, Jason M; Colavin, Alexandre; Shi, Handuo et al. (2016) A Comprehensive, CRISPR-based Functional Analysis of Essential Genes in Bacteria. Cell 165:1493-1506
Du, Dan; Qi, Lei S (2016) An Introduction to CRISPR Technology for Genome Activation and Repression in Mammalian Cells. Cold Spring Harb Protoc 2016:pdb.top086835
Gao, Yuchen; Xiong, Xin; Wong, Spencer et al. (2016) Complex transcriptional modulation with orthogonal and inducible dCas9 regulators. Nat Methods 13:1043-1049
Dominguez, Antonia A; Lim, Wendell A; Qi, Lei S (2016) Beyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation. Nat Rev Mol Cell Biol 17:5-15
Xiong, Xin; Chen, Meng; Lim, Wendell A et al. (2016) CRISPR/Cas9 for Human Genome Engineering and Disease Research. Annu Rev Genomics Hum Genet 17:131-54

Showing the most recent 10 out of 24 publications